{
    "organizations": [],
    "uuid": "bfb07f31295ea882a6af5bd9c36bb44c7ff2ce49",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-tesaro-says-topacio-data-demonstra/brief-tesaro-says-topacio-data-demonstrates-compelling-clinical-activity-of-zejula-in-patients-with-type-of-ovarian-cancer-idUSASC09TNT",
    "ord_in_thread": 0,
    "title": "BRIEF-Tesaro Says TOPACIO Data Demonstrates Compelling Clinical Activity Of Zejula In Patients With Type Of Ovarian Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 26 (Reuters) - Tesaro Inc:\n* DATA FROM TOPACIO TRIAL REPORTED AT SGO DEMONSTRATES COMPELLING CLINICAL ACTIVITY OF ZEJULA IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER\n* TESARO INC - ‍EFFICACY OF NIRAPARIB IN COMBINATION WITH AN ANTI-PD-1 MAB SURPASSES HISTORICAL EFFICACY BENCHMARKS FOR PD-1 OR PARP MONOTHERAPIES​\n* TESARO INC - COMBINATION OF NIRAPARIB WITH PEMBROLIZUMAB WAS WELL TOLERATED WITH AN INCIDENCE OF GRADE 3/4 THROMBOCYTOPENIA OF 9%\n* TESARO-POTENTIAL APPROACH TO REDUCE INCIDENCE OF GRADE 3 OR 4 THROMBOCYTOPENIA IDENTIFIED BASED ON RETROSPECTIVE ANALYSIS OF DATA FROM PHASE 3 NOVA TRIAL\n* TESARO - IN ADDITION TO THROMBOCYTOPENIA, OTHER MOST COMMONLY OBSERVED GRADE ≥3 ADVERSE EVENTS N STUDY INCLUDED ANEMIA AND NEUTROPENIA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-27T04:12:00.000+03:00",
    "crawled": "2018-03-27T11:54:17.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "tesaro",
        "inc",
        "data",
        "topacio",
        "trial",
        "reported",
        "sgo",
        "demonstrates",
        "compelling",
        "clinical",
        "activity",
        "zejula",
        "combination",
        "antibody",
        "patient",
        "platinum",
        "ovarian",
        "cancer",
        "tesaro",
        "inc",
        "niraparib",
        "combination",
        "mab",
        "surpasses",
        "historical",
        "efficacy",
        "benchmark",
        "parp",
        "tesaro",
        "inc",
        "combination",
        "niraparib",
        "pembrolizumab",
        "well",
        "tolerated",
        "incidence",
        "grade",
        "thrombocytopenia",
        "approach",
        "reduce",
        "incidence",
        "grade",
        "thrombocytopenia",
        "identified",
        "based",
        "retrospective",
        "analysis",
        "data",
        "phase",
        "nova",
        "trial",
        "tesaro",
        "addition",
        "thrombocytopenia",
        "commonly",
        "observed",
        "grade",
        "adverse",
        "event",
        "n",
        "study",
        "included",
        "anemia",
        "neutropenia",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}